Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.68 |
| ▸ | RXRB | P28702 | 2/20 | 0.68 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.66 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.66 |
| ▸ | MAP4K4 | O95819 | 7/20 | 0.61 |
| ▸ | ERN1 | O75460 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2689662 | 0.85 | MAP4K4 (0.72) | MKNK1MKNK2MAP4K4CA12CA1 | |
| SCHEMBL12607545 | 0.84 | MKNK1 (0.54) | RXRARXRBMKNK1MKNK2MAP4K4 | |
| SCHEMBL27998215 | 0.84 | MKNK1 (0.62) | MKNK1MKNK2MAP4K4ERN1CA12 | |
| SCHEMBL2690729 | 0.82 | NPC1 (0.64) | MKNK1MKNK2MAP4K4NPC1RAB9A | |
| SCHEMBL1002578 | 0.82 | CA2 (0.67) | MKNK1MKNK2MAP4K4ERN1CA12 | |
| SCHEMBL412461 | 0.81 | RXRA (1.00) | RXRARXRBMAP4K4ERN1 | |
| SCHEMBL30837227 | 0.79 | RXRA (0.68) | RXRARXRBMKNK1MKNK2NPC1 | |
| SCHEMBL17485202 | 0.79 | DHODH (0.66) | RXRARXRBMKNK1MKNK2MAP4K4 | |
| SCHEMBL29291743 | 0.79 | RXRA (0.61) | RXRARXRBMKNK1MKNK2MAP4K4 | |
| SCHEMBL8297932 | 0.77 | MAP4K4 (0.54) | MKNK1MKNK2MAP4K4ERN1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | claimed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | claimed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | claimed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | claimed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | claimed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | RXRA 4143/4885RXRB 3992/4885MKNK1 347/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | RXRA 4349/4885RXRB 4279/4885MKNK1 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.